NASDAQ
Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 and net income of $-190,886,000 for FY 2025, with a net profit margin of 0%. Revenue represents total sales while net income is the profit remaining after all expenses. The relationship between them reflects overall profitability.
No price data available for this timeframe.